Neuroepigenetic Mechanisms of Action of Ultrashort Peptides in Alzheimer's Disease

Ilina A, Khavinson V, Linkova N, Petukhov M. Int J Mol Sci. 2022.

Organ: brain-cognition · Type: review · Peptides: EDR, KED, Epitalon

PMID: 35457077

An open-access IJMS review hypothesizing that ultrashort peptides could act on Alzheimer-related gene expression via histones, DNA elements, and non-coding RNA — a mechanism essay, not a clinical trial.

Editorial summary of a 2022 International Journal of Molecular Sciences review (MDPI, open access: doi:10.3390/ijms23084259). Public pages cite PubMed; the DOI is the OA record. Read the paper: PMID 35457077.

Methods

Narrative review. The authors survey epigenetic themes in Alzheimer’s disease (DNA methylation, chromatin remodeling, histone marks, non-coding RNA) and pathogenetic strands they treat as linked — tau and amyloid misfolding, mitochondrial dysfunction, oxidative stress, blood–brain-barrier injury, neuroinflammation, and synaptic failure. They then collect published work on ultrashort peptides from the Khavinson line and state a hypothesis: that short peptides could regulate transcription by contacting histone proteins, cis- and trans-DNA elements, and effectors such as DNA/RNA-binding proteins and non-coding RNA. No new experiment is reported here.

Findings

The authors present ultrashort peptides as candidate neuroprotective compounds with a broad published spectrum and no side effects reported in the literature they cite. They frame peptide–chromatin interaction as a possible addition to multifunctional Alzheimer research. That is a mechanistic hypothesis built from prior papers.

This review does not show clinical benefit in Alzheimer’s disease. Follow the PMID and the OA DOI.